<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869761</url>
  </required_header>
  <id_info>
    <org_study_id>20-008380</org_study_id>
    <nct_id>NCT04869761</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Chronic Kidney Disease</brief_title>
  <official_title>Allogeneic Mesenchymal Stem Cell Therapy in Patients With Chronic Kidney Disease: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LaTonya J. Hickson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal&#xD;
      stem / stromal cell therapy in individuals with chronic kidney disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and/or serious adverse events</measure>
    <time_frame>22 months</time_frame>
    <description>Number of adverse events and/or serious adverse events associated with mesenchymal stem cells intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>Dose Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion</intervention_name>
    <description>Single MSC infusion of 150x10^6 cells at time zero; intravenous delivery</description>
    <arm_group_label>Dose Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions</intervention_name>
    <description>Two MSC infusions of 75x10^6 cells at time zero and three months; intravenous delivery</description>
    <arm_group_label>Dose Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 30-80 years.&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) 25-55 ml/min/1.73m^2&#xD;
&#xD;
          -  Spot urine albumin:creatinine â‰¥30 mg/g unless on Renin-angiotensin-aldosterone system&#xD;
             (RAAS) inhibition.&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin A1c greater than or equal to 11%.(in individuals with diabetes mellitus)&#xD;
&#xD;
          -  Anemia (hemoglobin less than 9g/dL)&#xD;
&#xD;
          -  Body weight greater than 150 kg or BMI greater than 50&#xD;
&#xD;
          -  Uncontrolled hypertension: sustained systolic blood pressure (SBP) greater than 155&#xD;
             mmHg at screening exam (a maximum of 3 screening visits will be allowed for&#xD;
             demonstration of blood pressure control)&#xD;
&#xD;
          -  Chronic hypotension: sustained SBP less than 85 mmHg at screening exam.&#xD;
&#xD;
          -  Glomerulonephritis not in partial or complete remission for 6 months (or&#xD;
             estimated/measured proteinuria greater than 10 grams/day)&#xD;
&#xD;
          -  Active glomerulonephritis (glomerular disease) include: ANCA associated&#xD;
             glomerulonephritis, post-infectious glomerulonephritis, lupus nephritis, amyloidosis,&#xD;
             or other monoclonal gammopathy of renal significance.&#xD;
&#xD;
          -  Nephrotic syndrome defined as proteinuria greater than 3.5g per 24 hours, plus&#xD;
             hypoalbuminemia (serum albumin less than or equal to 2.5g/L) and edema&#xD;
&#xD;
          -  Autosomal dominant or recessive polycystic kidney disease&#xD;
&#xD;
          -  Kidney failure requiring renal replacement therapy (hemodialysis, peritoneal dialysis,&#xD;
             or kidney transplantation)&#xD;
&#xD;
          -  Active immunosuppression therapy (including prednisone greater than or equal to 10mg&#xD;
             daily)&#xD;
&#xD;
          -  Kidney transplantation history&#xD;
&#xD;
          -  Solid organ transplantation history&#xD;
&#xD;
          -  Recent cardiovascular event (myocardial infarction, stroke, congestive heart failure)&#xD;
             within 6 months or uncontrolled cardiac arrhythmias&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease, asthma&#xD;
&#xD;
          -  History of blood clotting disorder (thromboembolism; pulmonary embolism, deep venous&#xD;
             thrombosis)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active hepatitis B or C, or HIV infection&#xD;
&#xD;
          -  History of allergic reaction to cellular products (ie. blood transfusions, platelets)&#xD;
&#xD;
          -  Active tobacco use&#xD;
&#xD;
          -  Illicit drug use and excessive alcohol use presence of psychosocial issues (e.g.,&#xD;
             uncontrolled mental illness, unpredictable childcare or eldercare responsibilities,&#xD;
             irregular/inflexible work schedule) that may interfere with the ability to complete&#xD;
             all study procedures&#xD;
&#xD;
          -  Subjects anticipating prolonged travel or other physical restrictions that would&#xD;
             prohibit return for scheduled study visits&#xD;
&#xD;
          -  Inability or unwilling to have magnetic resonance imaging (MRI) or computed tomography&#xD;
             (CT) studies&#xD;
&#xD;
          -  Inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LaTonya Hickson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Simon</last_name>
    <phone>(904) 953-4205</phone>
    <email>Simon.FedericoRey@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas George</last_name>
    <phone>(904) 953-3880</phone>
    <email>George.Andreas@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaTonya Hickson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>LaTonya J. Hickson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stem cell</keyword>
  <keyword>mesenchymal stem cell</keyword>
  <keyword>mesenchymal stromal cell</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>diabetic nephropathy</keyword>
  <keyword>diabetic kidney disease</keyword>
  <keyword>kidney</keyword>
  <keyword>GFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

